CTOs on the Move

Primmune Therapeutics

www.primmunerx.com

 
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.primmunerx.com
  • JLABS San Diego 3210 Merryfield Road
    San Diego, CA USA 92121
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Primmune Therapeutics raised $27.4M on 10/27/2020

Similar Companies

Morphogenesis

Morphogenesis is a clinical stage company developing novel cell and gene therapies based on distinct and synergistic technology platforms. Our mission is to change the way chronic diseases are treated by engaging the innate intelligence of the body.

Kira Pharmaceuticals

Kira Pharmaceuticals is pioneering complement drug discovery to deliver transformative therapies for people with complement-mediated diseases

Critical Path Services

Critical Path Services is a Garnet Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Invivyd

Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd`s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications.

Apollomics

At Apollomics, we are a purpose driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve.